Clover Health Corp (CLOV) shares surged in pre-market trading on October 11, 2024, following positive developments related to its Medicare Advantage plans and benchmark rates.
The company's Medicare Advantage PPO plans earned a coveted 4-star rating for the 2025 plan year, outperforming larger rivals like Humana. This high rating is expected to boost Clover Health's ability to attract and retain Medicare Advantage enrollees, a key driver of growth for the company.
Furthermore, Clover Health announced that due to its PPO contract receiving a 4.0-star rating, it expects a general 5% increase in benchmark rates for the 2026 payment year. This increase in benchmark rates is expected to translate into higher revenues for the company, providing a direct financial benefit from its strong quality rating.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。